Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOD1 | P00441 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3786477 | 0.84 | SOD1 (0.39) | SOD1SLC6A4MAOAPOLB | |
| SCHEMBL1043789 | 0.84 | SOD1 (0.44) | SOD1SLC6A4MAOAIDO1POLB | |
| SCHEMBL17703530 | 0.77 | SOD1 (0.35) | SOD1IDO1 | |
| SCHEMBL3790308 | 0.77 | TSHR (0.41) | IDO1 | |
| SCHEMBL172803 | 0.77 | TSHR (0.50) | IDO1 | |
| SCHEMBL12838344 | 0.75 | SLC6A4 (0.32) | SLC6A4MAOAIDO1 | |
| SCHEMBL3792826 | 0.75 | CYP3A4 (0.48) | SOD1SLC6A4MAOA | |
| SCHEMBL17485227 | 0.72 | PTGS2 (0.35) | SOD1SLC6A4MAOA | |
| SCHEMBL2866808 | 0.71 | SLC6A4 (0.39) | SLC6A4MAOA | |
| SCHEMBL29993511 | 0.70 | GRM5 (0.47) | SLC6A4MAOAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2018-06-07 | — | — | US | disclosed |
| US-9873687-B2 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | ACTIVE BIOTECH AB (SE) | 2018-01-23 | — | — | US | disclosed |
| WO-2014184234-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | ACTIVE BIOTECH AB (SE) | 2014-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155330-A1 | N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS | S100A9, S100B, S100A10 | SOD1 3109/4885SLC6A4 1517/4885MAOA 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.